Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E NRAS Q61K||melanoma||sensitive||XL888||Preclinical||Actionable||In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686).||22351686|
|BRAF V600E NRAS Q61K||melanoma||resistant||Vemurafenib||Preclinical||Actionable||In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).||21107323|
|BRAF V600E NRAS Q61K||melanoma||resistant||Dabrafenib||Preclinical||Actionable||In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).||22389471|
|BRAF V600E NRAS Q61K||melanoma||sensitive||Dabrafenib + Trametinib||Preclinical||Actionable||In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).||22389471|
|BRAF V600E NRAS Q61K||lung adenocarcinoma||predicted - resistant||Dabrafenib + Trametinib||Case Reports/Case Series||Actionable||In a clinical case study, a breast cancer patient with metastatic lung adenocarcinoma harboring BRAF V600E developed progressive disease after initial response to Talfinlar (dabrafenib) and Mekinist (trametinib) combination therapy, NRAS Q61K was identified as an acquired mutation after disease progression (PMID: 29631033).||29631033|
|BRAF V600E NRAS Q61K||colorectal cancer||predicted - resistant||Panitumumab + Vemurafenib||Case Reports/Case Series||Actionable||In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 40 weeks to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, NRAS Q61K was identified as an acquired mutation at the time of progression (PMID: 28951457).||28951457|
|BRAF V600E NRAS Q61K||melanoma||resistant||Vemurafenib||Case Reports/Case Series||Actionable||In a clinical case study, a melanoma patient harboring BRAF V600E experienced progressive disease after response to treatment Zelboraf (vemurafenib), and was found to have acquired NRAS Q61K (PMID: 34376578).||34376578|
|BRAF V600E NRAS Q61K||melanoma||sensitive||ASTX029||Preclinical - Cell culture||Actionable||In a preclinical study, ASTX029 treatment reduced Erk and Rsk phosphorylation and inhibited growth of a melanoma cell line harboring BRAF V600E and expressing NRAS Q61K in culture (PMID: 34330842).||34330842|